• Rua Bioscience signed a distribution and license agreement to import and sell Pharmala Biotech Holdings’ GMP-grade LaNeo MDMA in New Zealand.
• Deal targets PTSD treatment following Medsafe’s Sept. 4, 2026 authorization for two psychiatrists to prescribe pharmaceutical-grade MDMA.
• Rua will supply 40 mg LaNeo MDMA capsules to authorized prescribers; initial shipment will be on consignment to limit upfront capital.
• PharmAla terminated its prior exclusive New Zealand distribution agreement with Veridion on Sept. 1, 2026, clearing the way for Rua.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081615PRIMZONEFULLFEED9841796) on October 08, 2026, and is solely responsible for the information contained therein.